Laboratorios Farmaceuticos Rovi Stock Target Price
| LABFF Stock | USD 90.61 0.00 0.00% |
Fundamental analysis of Laboratorios Farmaceuticos allows traders to better anticipate movements in Laboratorios Farmaceuticos' stock price by examining its financial health and performance throughout various phases of its business cycle.
Laboratorios |
Laboratorios Target Price Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Laboratorios Farmaceuticos' direct or indirect competition against its Target Price to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Laboratorios Farmaceuticos could also be used in its relative valuation, which is a method of valuing Laboratorios Farmaceuticos by comparing valuation metrics of similar companies.Laboratorios Farmaceuticos is currently under evaluation in target price category among its peers.
Laboratorios Fundamentals
| Return On Equity | 0.39 | |||
| Return On Asset | 0.18 | |||
| Profit Margin | 0.23 % | |||
| Operating Margin | 0.28 % | |||
| Current Valuation | 1.93 B | |||
| Shares Outstanding | 51.32 M | |||
| Shares Owned By Insiders | 60.25 % | |||
| Shares Owned By Institutions | 17.46 % | |||
| Price To Earning | 15.16 X | |||
| Price To Book | 6.51 X | |||
| Price To Sales | 3.45 X | |||
| Revenue | 648.68 M | |||
| Gross Profit | 379.83 M | |||
| EBITDA | 204.66 M | |||
| Net Income | 153.08 M | |||
| Cash And Equivalents | 158.94 M | |||
| Cash Per Share | 2.98 X | |||
| Total Debt | 52.52 M | |||
| Debt To Equity | 0.18 % | |||
| Current Ratio | 1.77 X | |||
| Book Value Per Share | 8.28 X | |||
| Cash Flow From Operations | 149.44 M | |||
| Earnings Per Share | 3.37 X | |||
| Number Of Employees | 1.75 K | |||
| Beta | 0.47 | |||
| Market Capitalization | 2.62 B | |||
| Total Asset | 732.68 M | |||
| Z Score | 29.4 | |||
| Annual Yield | 0.02 % | |||
| Net Asset | 732.68 M |
About Laboratorios Farmaceuticos Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Laboratorios Farmaceuticos Rovi's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Laboratorios Farmaceuticos using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Laboratorios Farmaceuticos Rovi based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Laboratorios Pink Sheet
Laboratorios Farmaceuticos financial ratios help investors to determine whether Laboratorios Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Laboratorios with respect to the benefits of owning Laboratorios Farmaceuticos security.